Biochemical and pharmacological characterization of FR134043, a novel elastase inhibitor

被引:13
|
作者
Shinguh, Y [1 ]
Yamazaki, A [1 ]
Inamura, N [1 ]
Fujie, K [1 ]
Okamoto, M [1 ]
Nakahara, K [1 ]
Notsu, Y [1 ]
Okuhara, M [1 ]
Ono, T [1 ]
机构
[1] Fujisawa Pharmaceut Co Ltd, Exploratory Res Labs, Tsukuba, Ibaraki 30026, Japan
关键词
FR134043; elastase inhibitor; elastase; adult respiratory distress syndrome; disseminated intravascular coagulation; septic shock; pulmonary emphysema; hemorrhage; edema;
D O I
10.1016/S0014-2999(98)00028-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
FR 134043, disodium(Z1S,15S,18S,24S,27R,29S,34S,37R)-29-benzyl-21-ethylidene-27-hydroxy-15-isobutyrylamino-34-isopropyl-31,37-dimethyl-10,16,19,22,30,32,35,38-octaoxo-36-oxa-9,11,17,20,23,28,31,33-octaazatetracyclo[16.13.61(24, 28).0(3, 8)]octatriconta-3,5,7-trien-5,6-diyl disulfate, is a water-soluble inhibitor of human neutrophil elastase with a molecular mass of 1166.15 Da. FR134043 demonstrated a characteristic competitive inhibition of human neutrophil elastase with a K-i of 8 nM. In studies using synthetic substrates, FR134043 inhibited both neutrophil elastase activity and porcine pancreatic elastase activity with IC50 values of 35 nM and 49 nM respectively. FR134043 also inhibited hydrolysis of bovine neck ligament elastin by human neutrophil elastase with an IC50 value of 210 nM. In in vivo experiments, FR134043 protected animals against human neutrophil elastase (50 mu g/animal)-induced lung hemorrhage in hamsters with an ED50 value of 3.1 mu g/animal for intratracheal administration and 5.0 mg/kg for intravenous administration. Subcutaneous treatment with FR134043 significantly suppressed human neutrophil elastase (20 mu g/paw)-induced paw edema in mice with an ED50 value of 3.3 mg/kg when evaluated 4 h after elastase injection. The potency of FR134043 given intratracheally to protect against porcine pancreatic elastase (100 mu g/animal)-induced emphysema in hamsters was relatively low (Quasi-static lung compliance; ED50 = 1590 mu g/animal) compared to that in acute animal models. FR134043 (10 mg/kg per h i.v. infusion) significantly improved lipopolysaccharide (0.25 mg/kg per h i.v. infusion)-induced thrombocytopenia and some coagulation parameters in rats. These results suggest that systemic administration of FR134043 would be advantageous over intratracheal administration of FR134043 for the treatment of adult respiratory distress syndrome, septic shock and pulmonary emphysema and other pathophysiologic conditions in which elastases are thought to be involved. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:299 / 308
页数:10
相关论文
共 50 条
  • [41] Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain
    Thirunavukkarasu, K.
    Swearingen, C. A.
    Oskins, J. L.
    Lin, C.
    Bui, H. H.
    Jones, S. B.
    Pfeifer, L. A.
    Norman, B. H.
    Mitchell, P. G.
    Chambers, M. G.
    OSTEOARTHRITIS AND CARTILAGE, 2017, 25 (06) : 935 - 942
  • [42] A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - Part I: Pharmacological characterization
    Wang, Yi-Xin
    Zhao, Lei
    Nagashima, Mariko
    Vincelette, Jon
    Sukovich, Drew
    Li, Weiwei
    Subramanyam, Babu
    Yuan, Shendong
    Emayan, Kumar
    Islam, Imadul
    Hrvatin, Paul
    Bryant, Judi
    Light, David R.
    Vergona, Ronald
    Morser, John
    Buckman, Brad O.
    THROMBOSIS AND HAEMOSTASIS, 2007, 97 (01) : 45 - 53
  • [43] True interaction mode of porcine pancreatic elastase with FR136706, a potent peptidyl inhibitor
    Kinoshita, T
    Nakanishi, I
    Sato, A
    Tada, T
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (01) : 21 - 24
  • [44] Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor
    Kolte, D.
    Bryant, J. W.
    Holsworth, D.
    Wang, J.
    Akbari, P.
    Gibson, G. W.
    Shariat-Madar, Z.
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 162 (07) : 1639 - 1649
  • [45] Biochemical characterization and pharmacological properties of a phospholipase A(2) myotoxin inhibitor from the plasma of the snake Bothrops asper
    Lizano, S
    Lomonte, B
    Fox, JW
    Gutierrez, JM
    BIOCHEMICAL JOURNAL, 1997, 326 : 853 - 859
  • [46] BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERIZATION OF DIFFERENT BENZODIAZEPINE RECEPTORS
    SIEGHART, W
    DEVELOPMENTS IN NEUROSCIENCE, 1984, 17 : 419 - 423
  • [47] BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERIZATION OF FISH COLLAGEN HYDROLYSATES
    Schadow, S.
    Siebert, H-C.
    Lochnit, G.
    Rickert, M.
    Steinmeyer, J.
    OSTEOARTHRITIS AND CARTILAGE, 2014, 22 : S325 - S325
  • [48] Biochemical properties and primary structure of elastase inhibitor AFUEl from Aspergillus fumigatus
    Okumura, Yoshiyuki
    Matsui, Takeshi
    Ogawa, Kenji
    Uchiya, Kei-ichi
    Nikai, Toshiaki
    JOURNAL OF MEDICAL MICROBIOLOGY, 2008, 57 (07) : 803 - 808
  • [49] Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia
    Jain, M. R.
    Joharapurkar, A. A.
    Pandya, V.
    Patel, V.
    Joshi, J.
    Kshirsagar, S.
    Patel, K.
    Patel, P. R.
    Desai, R. C.
    DRUG RESEARCH, 2016, 66 (02) : 107 - 112
  • [50] Characterization and Pharmacological Properties of a Novel Multifunctional Kunitz Inhibitor from Erythrina velutina Seeds
    Machado, Richele J. A.
    Monteiro, Norberto K. V.
    Migliolo, Ludovico
    Silva, Osmar N.
    Pinto, Michele F. S.
    Oliveira, Adeliana S.
    Franco, Octavio L.
    Kiyota, Sumika
    Bemquerer, Marcelo P.
    Uchoa, Adriana F.
    Morais, Ana H. A.
    Santos, Elizeu A.
    PLOS ONE, 2013, 8 (05):